SYLVANT is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is Siltuximab.
| Product ID | 57894-420_62686022-7ea4-11e8-8599-a18b9d46d017 |
| NDC | 57894-420 |
| Product Type | Human Prescription Drug |
| Proprietary Name | SYLVANT |
| Generic Name | Siltuximab |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2014-04-23 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125496 |
| Labeler Name | Janssen Biotech, Inc. |
| Substance Name | SILTUXIMAB |
| Active Ingredient Strength | 100 mg/1 |
| Pharm Classes | Interleukin-6 Antagonist [EPC],Interleukin-6 Antagonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2014-04-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA125496 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2014-04-23 |
| Marketing End Date | 2021-01-31 |
| Ingredient | Strength |
|---|---|
| SILTUXIMAB | 100 mg/1 |
| SPL SET ID: | 451f535b-8b6b-4ecf-9f19-d921b72eea39 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 57894-420 | SYLVANT | siltuximab |
| 57894-421 | SYLVANT | siltuximab |
| 73090-420 | Sylvant | Siltuximab |
| 73090-421 | Sylvant | Siltuximab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() SYLVANT 86975538 4657836 Live/Registered |
JOHNSON & JOHNSON 2013-12-12 |
![]() SYLVANT 86142160 not registered Dead/Abandoned |
JOHNSON & JOHNSON 2013-12-12 |
![]() SYLVANT 77887266 not registered Dead/Abandoned |
JOHNSON & JOHNSON 2009-12-07 |